Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 12/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | DAO | P14920 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464129 | 1.00 | PGR (0.78) | PGRPOLBDAOMAOBB3GNT2 | |
| SCHEMBL28836860 | 0.91 | PGR (0.67) | PGRPOLBDAOMAOBB3GNT2 | |
| SCHEMBL4084714 | 0.87 | PGR (0.64) | PGRPOLBDAOMAOBFEN1 | |
| SCHEMBL9601771 | 0.84 | PGR (0.57) | PGRPOLBDAOMAOBFEN1 | |
| SCHEMBL2975327 | 0.81 | POLB (0.62) | PGRPOLBDAOMAOBB3GNT2 | |
| SCHEMBL17807767 | 0.81 | MAOB (0.68) | PGRPOLBMAOBB3GNT2 | |
| SCHEMBL29414802 | 0.80 | PGR (0.60) | PGRPOLBMAOBB3GNT2 | |
| SCHEMBL20987129 | 0.80 | PGR (0.60) | PGRPOLBMAOBB3GNT2 | |
| SCHEMBL2968866 | 0.80 | PGR (0.72) | PGRPOLBDAOMAOBB3GNT2 | |
| SCHEMBL2966714 | 0.79 | PGR (0.66) | PGRPOLBDAOMAOBB3GNT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345900-B1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | BEBETTER MED INC (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | BEBETTER MED INC. (CN) | 2022-03-08 | — | — | US | disclosed |
| US-20200331891-A9 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200165227-A1 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3345900-A1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | Guangzhou Bebetter Medicine Technology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | disclosed |
| EP-1664036-B1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | PFIZER INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7776885-B2 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER INC. | 2005-07-07 | — | — | US | disclosed |
| US-5534521-A | SEROTONIN ANTAGONISTS | G. D. SEARLE & CO. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5521193-A | SEROTONIN AGONISTS AND ANTAGONISTS | G. D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5280028-A | Containing ketone structure in position2 | G. D. SEARLE & CO. (US) | 1994-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331891-A9 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, KRAS | PGR 1522/4885POLB 1360/4885DAO 1342/4885 |
| US-20200165227-A1 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, KRAS | PGR 1522/4885POLB 1360/4885DAO 1342/4885 |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | EGFR, ERBB2, KRAS | PGR 1522/4885POLB 1360/4885DAO 1342/4885 |
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | HTR4, GPR4, HTR5A | PGR 2397/4885POLB 4732/4885DAO 2801/4885 |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | HTR4, GPR4, HTR5A | PGR 2397/4885POLB 4732/4885DAO 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.